Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis

PURPOSE: To evaluate the efficacy and safety of lenvatinib plus programmed death-1 (PD-1) antibody as postoperative adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risks of recurrence. PATIENTS AND METHODS: A series of 137 patients with HCC at high risks of recurrence who un...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Jingzhong, Wang, Zhengzheng, Yuan, Kun, Yang, Yi, Zhou, Yanzhao, Li, Qingjun, Yang, Nanmu, Zhao, Haitao, Zhao, Hong, Zhou, Jinxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493137/
https://www.ncbi.nlm.nih.gov/pubmed/37701564
http://dx.doi.org/10.2147/JHC.S424616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493137/
https://www.ncbi.nlm.nih.gov/pubmed/37701564
http://dx.doi.org/10.2147/JHC.S424616

Ejemplares similares